The potential value of Copeptin and Pentraxin3 for evaluating the severity of coronary stenosis in patients with coronary artery disease
Open Access
- 1 January 2021
- journal article
- research article
- Published by Elsevier in Clinical Biochemistry
- Vol. 87, 32-38
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 21 references indexed in Scilit:
- Association Of Serum Pentraxin-3 And High-Sensitivity C-Reactive Protein With The Extent Of Coronary Stenosis In Patients Undergoing Coronary AngiographyJournal of Medical Biochemistry, 2015
- Associations between pentraxin 3 and severity of coronary artery diseaseBMJ Open, 2015
- Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart diseaseNature, 2015
- Comparison of cystatin-C and pentraxin-3 in coronary atherosclerosisCoronary Artery Disease, 2014
- CopeptinJournal of Cardiovascular Medicine, 2013
- Pentraxin-3 Predicts Functional Recovery and 1-Year Major Adverse Cardiovascular Events After Rehabilitation of Cardiac Surgery PatientsJournal of Cardiopulmonary Rehabilitation and Prevention, 2012
- N-Terminal Probrain Natriuretic Peptide and C-reactive Protein in Stable Coronary Heart DiseaseThe American Journal of Medicine, 2006
- Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene studyEuropean Heart Journal, 2004
- Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.Circulation, 1994
- A more meaningful scoring system for determining the severity of coronary heart diseaseThe American Journal of Cardiology, 1983